Literature DB >> 17922867

Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha.

Anders Lidgren1, Anders Bergh, Kjell Grankvist, Torgny Rasmuson, Börje Ljungberg.   

Abstract

OBJECTIVE: To evaluate transcription factor hypoxia inducible factor-1 alpha (HIF-1 alpha) activity, by analysing a target gene for HIF-1 alpha, glucose transporter-1 (GLUT-1), using a tissue microarray (TMA) in different types of renal cell carcinoma (RCC, a tumour with a variable clinical course, partly due to angiogenic activity), as angiogenesis is important for tumour progression and metastatic spread, and is activated by hypoxia. PATIENTS AND METHODS: GLUT-1 and HIF-1 alpha expressions were semiquantitatively analysed using immunohistological staining of a prepared TMA, using samples from 187 patients, including 148 with conventional, 26 with papillary and 13 with chromophobe RCC.
RESULTS: GLUT-1 staining was found mainly in the cytoplasm. The tumours were subdivided into GLUT -1(LOW) and GLUT-1(HIGH), based on staining intensity. There was a significant difference in GLUT-1 expression between RCC types (P < 0.05). In conventional RCC, GLUT-1 had no correlation with clinicopathological variables. By contrast there was a correlation with tumour stage in papillary RCC. There was an insignificant trend to better survival of patients with GLUT-1(LOW) expression in both conventional and papillary RCC. GLUT-1 correlated significantly (P = 0.008) with HIF-1 alpha.
CONCLUSIONS: Most patients with conventional RCC had GLUT-1(HIGH) staining and there was a significant correlation with HIF-1 alpha. In papillary RCC, GLUT-1 expression was associated with stage; GLUT-1 expression was significantly higher in conventional RCC than in papillary and chromophobe RCC. GLUT-1(LOW) in both papillary and conventional RCC appeared to correspond with a better prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922867     DOI: 10.1111/j.1464-410X.2007.07238.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

1.  Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma.

Authors:  Ashley H Davis-Yadley; Andrea M Abbott; Jose M Pimiento; Dung-Tsa Chen; Mokenge P Malafa
Journal:  Pancreas       Date:  2016-08       Impact factor: 3.327

2.  Inhibition of glucose-transporter 1 (GLUT-1) expression reversed Warburg effect in gastric cancer cell MKN45.

Authors:  Tian-Biao Zhang; Ying Zhao; Zhao-Xue Tong; Yi-Fu Guan
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis.

Authors:  Olca Basturk; Rajendra Singh; Ecmel Kaygusuz; Serdar Balci; Nevra Dursun; Nil Culhaci; N Volkan Adsay
Journal:  Pancreas       Date:  2011-03       Impact factor: 3.327

4.  Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy.

Authors:  María Virumbrales-Muñoz; Jose M Ayuso; Jack R Loken; Kathryn M Denecke; Shujah Rehman; Melissa C Skala; E Jason Abel; David J Beebe
Journal:  Biomaterials       Date:  2022-03-11       Impact factor: 15.304

5.  Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma.

Authors:  Xiao-Hong Wu; Su-Ping Chen; Jian-Ying Mao; Xue-Xian Ji; Hong-Tian Yao; Shui-Hong Zhou
Journal:  Oncol Lett       Date:  2012-09-26       Impact factor: 2.967

Review 6.  Cancer's craving for sugar: an opportunity for clinical exploitation.

Authors:  S Yeluri; B Madhok; K R Prasad; P Quirke; D G Jayne
Journal:  J Cancer Res Clin Oncol       Date:  2009-05-05       Impact factor: 4.553

7.  Potential role of sugar transporters in cancer and their relationship with anticancer therapy.

Authors:  Moisés Blanco Calvo; Angélica Figueroa; Enrique Grande Pulido; Rosario García Campelo; Luís Antón Aparicio
Journal:  Int J Endocrinol       Date:  2010-07-18       Impact factor: 3.257

8.  Regulation of hypoxia inducible factor-1α expression by the alteration of redox status in HepG2 cells.

Authors:  Wen-sen Jin; Zhao-lu Kong; Zhi-fen Shen; Yi-zun Jin; Wu-kui Zhang; Guang-fu Chen
Journal:  J Exp Clin Cancer Res       Date:  2011-05-19

9.  Pseudoginsengenin DQ exerts antitumour activity against hypopharyngeal cancer cells by targeting the HIF-1α-GLUT1 pathway.

Authors:  Sanchun Wang; Yu Cai; Qingjie Feng; Jing Gao; Bo Teng
Journal:  Cancer Cell Int       Date:  2021-07-19       Impact factor: 5.722

10.  Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer.

Authors:  Danuta Martuszewska; Börje Ljungberg; Martin Johansson; Göran Landberg; Cecilia Oslakovic; Björn Dahlbäck; Sassan Hafizi
Journal:  PLoS One       Date:  2009-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.